| 前收盘价格 | 41.09 |
| 收盘价格 | 41.10 |
| 成交量 | 322,136 |
| 平均成交量 (3个月) | 786,741 |
| 市值 | 1,885,286,144 |
| 价格/销量 (P/S) | 14.04 |
| 股市价格/股市净资产 (P/B) | 19.27 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2026 |
| 营业毛利率 | -150.68% |
| 营业利益率 (TTM) | -182.26% |
| 稀释每股收益 (EPS TTM) | -3.01 |
| 季度收入增长率 (YOY) | 7.80% |
| 总债务/股东权益 (D/E MRQ) | 481.07% |
| 流动比率 (MRQ) | 5.65 |
| 营业现金流 (OCF TTM) | -107.06 M |
| 杠杆自由现金流 (LFCF TTM) | -54.76 M |
| 资产报酬率 (ROA TTM) | -29.80% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | UroGen Pharma Ltd. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | -1.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.83 |
|
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 6.87% |
| 机构持股比例 | 105.32% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Jefferies Financial Group Inc. | 31 Mar 2026 | 2,199,652 |
| Acorn Capital Advisors, Llc | 31 Mar 2026 | 1,673,420 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合